Acalnib 100mg Capsule Supplier USA | Pharmaceutical Exporter from India

Acalnib 100mg Capsule: Selective BTK Inhibition for CLL, SLL, and MCL

Are you looking for a trusted Acalnib 100mg Capsule exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of next-generation targeted therapies. We maintain a high-authority, regulatory-compliant supply chain serving the USA, UK, Australia, and South Africa, ensuring that life-saving hematology treatments reach healthcare providers with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Acalnib 100mg?

Acalnib 100mg contains the active pharmaceutical ingredient Acalabrutinib. It is a second-generation, highly selective Bruton's Tyrosine Kinase (BTK) inhibitor. Compared to earlier treatments, Acalnib is designed for greater potency and fewer off-target effects, leading to improved tolerability for patients.

Manufactured by Hetero Healthcare, Acalnib is a high-quality version of the brand Calquence. For international B2B procurement, Acalnib 100mg offers a clinically validated, cost-effective solution for treating specific types of B-cell malignancies, helping patients manage blood cancers with a precise oral regimen.

Primary Therapeutic Indications

Acalnib 100mg Capsule is clinically indicated for the treatment of:

1. Chronic Lymphocytic Leukemia (CLL) & Small Lymphocytic Lymphoma (SLL): For adult patients with previously untreated or relapsed/refractory CLL or SLL.

2. Mantle Cell Lymphoma (MCL): For adult patients who have received at least one prior therapy.

Mechanism of Action: How Acalnib Works

Acalnib targets the signaling pathways that allow cancer cells to survive and multiply:

• Inhibiting BTK: Bruton's Tyrosine Kinase (BTK) is a crucial protein in the B-cell receptor signaling pathway. In certain blood cancers, this pathway is hyperactive, causing uncontrolled B-cell growth.

• Disrupting Cancer Signals: Acalnib forms a covalent bond with the BTK enzyme, permanently blocking its activity. This disruption triggers apoptosis (programmed cell death) in malignant B-cells.

• High Selectivity: Acalnib is engineered to be highly selective, meaning it targets BTK while minimizing interactions with other kinases. This reduces the risk of side effects like atrial fibrillation and bleeding often seen with older inhibitors.

Administration and Safety Guidelines

• Standard Dosage: The typical dose is 100mg (one capsule) taken orally approximately every 12 hours (twice daily).

• Flexible Dosing: Acalnib can be taken with or without food. Capsules must be swallowed whole with water—do not crush, chew, or dissolve.

• Key Precautions:

• Monitoring Blood Counts: Regular blood tests are required to monitor for anemia, neutropenia, and thrombocytopenia.

• Cardiac Health: Patients should be monitored for signs of heart rhythm disorders (arrhythmias).

• Infection Risk: Promptly report any signs of fever or respiratory infection.

• Acid Reducers: Certain antacids and PPIs can interfere with absorption; consult your oncologist for specific timing instructions.

• 
  

Why Source Acalnib 100mg from Ernest Oncology?

• Authentic Indian Exporter: Direct access to genuine Hetero Healthcare inventory, ensuring 100% product integrity and competitive wholesale pricing.

• Cold-Chain & Logistics Expertise: Proven experience in navigating international customs and regulatory requirements for the USA, UK, Australia, and South Africa.

• Global Trust: As part of Ernest Pharmaceutical Pvt. Ltd., we provide full documentation, including GMP compliance and Certificates of Analysis (COA).

• Bulk Supply Stability: We specialize in fulfilling large-scale orders for oncology centers, government tenders, and regional medical distributors.